A61K 39/116
Polyvalent bacterial antigens
A61K39/116 (Polyvalent bacterial antigens) appears on 99 US grants and 155 published applications in this corpus.
Search patents in A61K- Granted patents
- 99
- Published applications
- 155
- Assignees
- 72
- Inventors
- 283
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 2 |
| 2007 | 0 | 1 |
| 2008 | 0 | 6 |
| 2009 | 0 | 7 |
| 2010 | 0 | 4 |
| 2011 | 0 | 2 |
| 2012 | 2 | 2 |
| 2013 | 3 | 7 |
| 2014 | 6 | 3 |
| 2015 | 5 | 4 |
| 2016 | 5 | 6 |
| 2017 | 5 | 4 |
| 2018 | 8 | 15 |
| 2019 | 4 | 11 |
| 2020 | 11 | 15 |
| 2021 | 12 | 15 |
| 2022 | 4 | 10 |
| 2023 | 9 | 10 |
| 2024 | 12 | 12 |
| 2025 | 9 | 9 |
| 2026 | 4 | 8 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F15 Sep 2026US 12,734,229 B2Inventprise, LLC
- Proteins and immunizing compositions containing Klebsiella proteins and methods of use28 Jul 2026US 12,691,167 B2Vaxxinova US, Inc.
- Immunogenic composition comprising multivalent Streptococcus pneumoniae polysaccharide-protein conjugates14 Jul 2026US 12,678,494 B2Celltrion Inc.
- CRA4S1 gene, encoded CRA4S1 protein, and application17 Feb 2026US 12,552,841 B2Zhenjiang Yangtze Green Biotechnology Co., Ltd.
- Meningococcus vaccines2 Dec 2025US 12,485,164 B2Glaxosmithkline Biologicals SA
- Materials and Methods For Cell-Free Expression of Vaccine Epitope Concatemers27 Aug 2026US 2026/0250332 A1Leidos, Inc.
- Vaccine against klebsiella pneumoniae16 Jul 2026US 2026/0199445 A1Idorsia Pharmaceuticals Ltd
- Vaccine against klebsiella pneumoniae28 May 2026US 2026/0144856 A1Idorsia Pharmaceuticals Ltd
- Multiple antigen presenting system (maps) cross-linked using a bifunctional fusion protein and its use in vaccines protein and its use in vaccines30 Apr 2026US 2026/0115270 A1Children's Medical Center Corporation
- Multivalent pneumococcal vaccines30 Apr 2026US 2026/0115271 A1Affinivax, Inc.
Most cited
By later US patents
- Process for manufacturing vaccines17US 8,329,184 B2Glaxosmithkline Biologicals SA · 2012
- Immunogenic composition16US 9,486,515 B2Glaxosmithkline Biologicals SA · 2016
- Multivalent pneumococcal vaccines12US 11,013,793 B2Affinivax, Inc. · 2021
- Immunogenic composition12US 8,398,983 B2Glaxosmithkline Biologicals SA · 2013
- Methods for preparing complex multivalent immunogenic conjugates12US 9,175,033 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2015